Table 2 Genes associated with epithelial ovarian cancer time to recurrence in analysis of tumors from the TCGA and Mayo Clinic (p < 0.01) for both adjusted and unadjusted analyses
From: Drug discovery using clinical outcome-based Connectivity Mapping: application to ovarian cancer
Analysis | Gene | TCGA study | Mayo Clinic study | ||||
|---|---|---|---|---|---|---|---|
HR | 95 % CI | P | HR | 95 % CI | P | ||
Adjusted for covariates | PTPRCAP | 0.71 | (0.56,0.89) | 0.004 | 0.14 | (0.04,0.40) | 3.6E-04 |
UBASH3A | 0.78 | (0.65,0.92) | 0.005 | 0.19 | (0.06,0.50) | 0.001 | |
PPBP | 1.18 | (1.04,1.33) | 0.009 | 5.79 | (1.94,17.21) | 0.002 | |
PVRIG | 0.73 | (0.58,0.91) | 0.005 | 0.28 | (0.12,0.62) | 0.002 | |
IGKV3-20 | 0.85 | (0.76,0.93) | 0.001 | 0.41 | (0.23,0.72) | 0.002 | |
FCRL5 | 0.84 | (0.74,0.95) | 0.008 | 0.30 | (0.14,0.65) | 0.002 | |
ITK | 0.83 | (0.72,0.95) | 0.008 | 0.30 | (0.13,0.66) | 0.003 | |
IGHV3OR16-12 | 0.85 | (0.77,0.94) | 0.002 | 0.47 | (0.28,0.78) | 0.004 | |
VANGL1 | 0.67 | (0.51,0.88) | 0.004 | 0.23 | (0.08,0.62) | 0.004 | |
SLC16A8 | 1.23 | (1.06,1.43) | 0.006 | 4.55 | (1.58,13.01) | 0.005 | |
IGKV3-20 | 0.89 | (0.82,0.96) | 0.004 | 0.50 | (0.30,0.83) | 0.007 | |
ACAP1 | 0.78 | (0.65,0.93) | 0.006 | 0.23 | (0.07,0.68) | 0.008 | |
Unadjusted for covariates | VANGL1 | 0.73 | (0.58,0.92) | 0.008 | 0.26 | (0.09,0.69) | 0.007 |
CD38 | 0.88 | (0.80,0.96) | 0.007 | 0.47 | (0.28,0.76) | 0.003 | |
ELA1 | 1.42 | (1.10,1.82) | 0.006 | 4.93 | (1.97,12.32) | 0.001 | |
PSME2 | 0.76 | (0.62,0.91) | 0.004 | 0.16 | (0.04,0.53) | 0.003 | |
UBD | 0.92 | (0.87,0.97) | 0.004 | 0.59 | (0.43,0.81) | 0.001 | |